A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

NCT04487574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: XC221
DRUG: Placebo

Sponsor

RSV Therapeutics LLC